Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer
- 31 May 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 181 (5), 1998-2008
- https://doi.org/10.1016/j.juro.2009.01.047
Abstract
Purpose: Androgen deprivation therapy has a variety of well recognized adverse effects including vasomotor flushing, loss of libido, fatigue, gynecomastia, anemia and osteoporosis. This review focuses on the more recently described metabolic complications of androgen deprivation therapy including obesity, insulin resistance and lipid alterations as well as the association of androgen deprivation therapy with diabetes and cardiovascular disease. Materials and Methods: We reviewed the medical literature using the PubMed® search terms prostate cancer, androgen deprivation therapy, gonadotropin-releasing hormone agonists, obesity, insulin resistance, lipids, diabetes, cardiovascular disease and myocardial infarction. We provide a focused review and our perspective on the relevant literature. Results: Androgen deprivation therapy decreases lean mass and increases fat mass. It also decreases insulin sensitivity while increasing low density lipoprotein cholesterol, high density lipoprotein cholesterol and triglycerides. Consistent with these adverse metabolic effects, androgen deprivation therapy may be associated with a greater incidence of diabetes and cardiovascular disease. Some of these androgen deprivation therapy related metabolic changes (obesity, insulin resistance and increased triglycerides) overlap with features of the metabolic syndrome. However, in contrast to the metabolic syndrome, androgen deprivation therapy increases subcutaneous fat and high density lipoprotein cholesterol. Conclusions: Androgen deprivation therapy increases obesity, decreases insulin sensitivity and adversely alters lipid profiles. It may be associated with a greater incidence of diabetes and cardiovascular disease. The benefits of androgen deprivation therapy should be weighed against these and other potential harms. Little is known about the optimal strategy to mitigate the adverse metabolic effects of androgen deprivation therapy. Thus, we recommend an emphasis on existing strategies for screening and treatment that have been documented to reduce the risk of diabetes and cardiovascular disease in the general population.Keywords
This publication has 60 references indexed in Scilit:
- Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31Journal of Clinical Oncology, 2009
- Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate CancerJAMA, 2008
- Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancerCancer, 2008
- Toremifene Improves Lipid Profiles in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase III StudyJournal of Clinical Oncology, 2008
- Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate CancerUrology, 2008
- Standards of Medical Care in Diabetes—2008Diabetes Care, 2008
- The rising prevalence of androgen deprivation among older American men since the advent of prostate‐specific antigen testing: a population‐based cohort studyBJU International, 2006
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891Journal of Clinical Oncology, 2006
- Noncancer Deaths in White Adult Cancer PatientsJNCI Journal of the National Cancer Institute, 1993